NCT02565953

Brief Summary

In recent years the use of paclitaxel releasing percutaneous transluminal angioplastic (PTA) balloon catheter is spreading in vascular pathology, mainly in stenosis infrainguinal arteries. This device combined the mechanical action of PTA balloon with the antiproliferative effects of paclitaxel. The use of these devices in venous pathology is limited. This devices could improve the treatment of renal dialysis arteriovenous fistula stenosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
134

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Oct 2015

Typical duration for phase_3

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 1, 2015

Completed
Same day until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

February 22, 2019

Status Verified

March 1, 2017

Enrollment Period

3 years

First QC Date

September 30, 2015

Last Update Submit

February 21, 2019

Conditions

Keywords

Vascular access devices obstruction

Outcome Measures

Primary Outcomes (1)

  • Freedom from target lesion revascularization

    Percentage of patients that do not need any revascularization proceeding during the following twelve months after catheter insertion.

    12 months

Study Arms (2)

Paclitaxel-releasing PTA balloon catheter

EXPERIMENTAL

Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.

Device: Paclitaxel-releasing PTA balloon catheter

PTA Balloon catheter

ACTIVE COMPARATOR

Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.

Device: PTA balloon catheter

Interventions

Paclitaxel-releasing PTA balloon catheter
PTA Balloon catheter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with renal dialysis with arteriovenous fistula (AVF) at least 3 months before.
  • Patient diagnosed with AVF stenosis by clinical and radiological criteria
  • Sign informed consent

You may not qualify if:

  • Pregnant or breastfeeding
  • Patients with AVF stenosis not could be treated with PTA catheter
  • Paclitaxel allergy
  • Iodinated contrast allergy
  • Local or systemic active infection
  • Life expectancy less than 12 moths

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Hospital Universitario Puerto Real

Puerto Real, Cádiz, 11510, Spain

Location

Hospital Universitario Reina Sofía

Córdoba, 14004, Spain

Location

Hospital Universitario Virgen de las Nieves

Granada, 18014, Spain

Location

Hospital Universitario Juan Ramón Jiménez

Huelva, 21005, Spain

Location

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 30, 2015

First Posted

October 1, 2015

Study Start

October 1, 2015

Primary Completion

October 1, 2018

Study Completion

October 1, 2018

Last Updated

February 22, 2019

Record last verified: 2017-03

Locations